Edition : 1
Year : 2014
Description :
The recent revolution in molecular biology offers exciting new opportunities for targeted radionuclide therapy. This up-to-date, comprehensive book, written by world-renowned experts, discusses the basic principles of radionuclide therapy, explores in detail the available treatments, explains the regulatory requirements, and examines likely future developments. The full range of clinical applications is considered, including thyroid cancer, hematological malignancies, brain tumors, liver cancer, bone and joint disease, and neuroendocrine tumors. The combination of theoretical background and practical information will provide the reader with all the knowledge required to administer radionuclide therapy safely and effectively in the individual patient. Careful attention is also paid to the role of the therapeutic nuclear physician in coordinating a diverse multidisciplinary team, which is central to the safe provision of treatment.
Table of contents : Front Matter....Pages i-xviii
A Historical Perspective on the Use of Radionuclides for Therapy....Pages 3-9
Therapeutic Radionuclides: Production, Physical Characteristics, and Applications....Pages 11-50
Rhenium-188 Generator-Based Radiopharmaceuticals for Therapy....Pages 51-81
Generator-Based Radiopharmaceuticals for PET Dosimetry Before, During, and After Endoradiotherapy....Pages 83-94
Cyclotron-Based Radiopharmaceuticals for Nuclear Medicine Therapy....Pages 95-103
Peptides for Nuclear Medicine Therapy: Chemical Properties and Production....Pages 105-123
Antibodies for Nuclear Medicine Therapy....Pages 125-138
Selective High Affinity Ligands: A New Class of Targeting Agents for Cancer Imaging and Therapy....Pages 139-150
Inorganic Radionuclides for Nuclear Medicine Therapy....Pages 151-163
Pharma Considerations for Timely Development of Therapeutic Radiopharmaceuticals....Pages 165-171
Economic and Industrial Considerations for Marketing of Therapeutic Radiopharmaceuticals....Pages 173-184
Radioimmunotherapy of Brain Tumors....Pages 187-198
Radiopeptide Therapy of Brain Tumors....Pages 199-205
Intracavitary Use of Radionuclides and Treatment of Meningiomas....Pages 207-214
Radio-Tympano-Sinu-Orthesis as a Treatment Option in Chronic Otitis Media and Paranasal Mucositis....Pages 215-221
Sodium Iodide Symporter in Thyroid Carcinoma....Pages 225-232
Gene Expression Analysis by DNA Microarray in Papillary and Follicular Differentiated Thyroid Cancer....Pages 233-244
Ablation Therapy with Radioiodine in Adults and Children with Differentiated Thyroid Cancer....Pages 245-258
Redifferentiation Therapy in Thyroid Cancer....Pages 259-268
Maximal Safe Dose Method of I-131 in the Management of Recurrent/Metastatic Differentiated Thyroid Carcinoma....Pages 269-274
Therapeutic Strategy of Papillary Microcarcinoma of the Thyroid Gland: A Nuclear Medicine Perspective....Pages 275-281
UICC Classifications 1997, 2002 and 2009: What is the Impact on Thyroid Cancer Mangement?....Pages 283-287
Radioiodine Remnant Ablation: A Critical Review....Pages 289-300
Follow-up of Thyroid Cancer Patients and Treatment of Distant Metastases....Pages 301-314
Medullary Thyroid Carcinoma....Pages 315-321
Treatment of Progressive Dedifferentiated and Medullary Thyroid Cancer with Radiolabeled Somatostatin Analogs....Pages 323-332
Radioiodine Therapy of Hyperthyroidism (Toxic Goiter, Hyperfunctioning Nodule) and Non-Toxic Goiter: Procedures and Guidelines....Pages 335-346
Radioiodine Therapy of Hyperthyroidism in Graves’ Disease....Pages 347-358
Radioembolization: Concepts and Procedures....Pages 361-377
Radioembolization: Clinical Results Hepatocellular Carcinoma....Pages 379-383
Radioembolization (Yttrium-90 Microspheres) for Metastatic Hepatic Malignancies....Pages 385-392
Rhenium-188 Lipiodol for the Treatment of Hepatocellular Carcinoma (HCC)....Pages 393-404
New Approaches: Combined Local and Multimodal Strategies in the Treatment of Complex Neuroendocrine Liver Metastases....Pages 405-420
Radiolabelled Bisphosphonates for Bone Pain Palliation....Pages 423-431
Radionuclide Therapy of Bone Metastases Using Rhenium-188 Hydroxyethylidene Diphosphonate....Pages 433-445
Treatment of Osteoblastic Skeletal Metastases by the Alpha-Emitting Bone-Seeker Radium-223....Pages 447-457
Radionuclide Therapy of Inflammatory Joint Diseases (Radiation Synovectomy, Radiosynoviorthesis)....Pages 459-493
Radionuclide Therapy for Bleeding Joints in Hemophilia....Pages 495-502
Non-Hodgkin Lymphoma: Radioimmunotherapy Using Iodine-131 Labeled Murine Anti-CD20 Antibodies ( 131 I-Tositumomab and Tositumomab, “Bexxar”)....Pages 505-525
Treatment of Lymphoma with 131 I-Chimeric Monoclonal Antibodies....Pages 527-533
Non-Hodgkin’s Lymphoma High Dose Therapy....Pages 535-542
Yttrium-90 Labelled Anti-CD20 Radioimmunotherapy with Stem Cells Support....Pages 543-550
Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan....Pages 551-556
Targeted Alpha Particle Therapy of Peritoneal Carcinomas....Pages 557-567
I-131 Meta Iodobenzylguanidine Therapy....Pages 571-581
Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors Expressing Somatostatin Receptors....Pages 583-603
Radioimmunotherapy of Tumors: Pretargeting with Bispecific Antibodies....Pages 607-615
Targeted Radionuclide Therapy of Prostate Cancer....Pages 617-628
Radioimmunotherapy of Neuroblastoma....Pages 629-638
Radioimmunotherapy in Metastatic Colorectal Cancer....Pages 639-661
Radioimmunotherapy of Renal Cancer....Pages 663-668
Myeloablative Radioimmunotherapy in Conditioning of Acute Leukemia, MDS, and Multiple Myeloma Prior to Hematological Stem Cell Transplantation....Pages 669-683
Endovascular Brachytherapy to Prevent Restenosis After Percutaneous Coronary Intervention....Pages 687-701
Locoregional Radionuclide Therapy of Primary and Metastatic Cancers....Pages 703-715
Radionuclide Therapy for Skin Malignancies....Pages 717-724
Epidermal Radionuclide Therapy: Dermatological High-Dose-Rate Brachytherapy for the Treatment of Basal and Squamous Cell Carcinoma....Pages 725-734
Patient-Specific Dosimetry, Radiobiology, and the Previously-Treated Patient....Pages 737-745
Nuclear Medicine Dose Assessment....Pages 747-757
Monte Carlo Methods in Nuclear Medicine....Pages 759-768
Dosimetry for Peptide Receptor Radionuclide Therapy....Pages 769-779
Comparison Between β -Emitting Isotopes and α -Emitters Regarding Their Effects on Cancer Cells....Pages 781-788
Hormesis by Low Dose Radiation Effects: Low-Dose Cancer Risk Modeling Must Recognize Up-Regulation of Protection....Pages 789-805
Animal Models for Developing Radiopharmaceuticals for Therapy....Pages 807-815
Dosimetry in Accidental Radiation Exposure....Pages 817-833
Potential Impact of Radiation Biology in Radiation Protection in Nuclear Medicine and Corresponding Regulatory Issues....Pages 835-842
Radiation Protection of Staff and Public....Pages 843-852
Effects of Music on the Psyche of Neuroendocrine Tumour Patients Undergoing Peptide Receptor Radionuclide Therapy....Pages 853-864
The Use of Dosimetry in the Planning of Patient Therapy....Pages 867-877
PET for Radiotherapy Planning....Pages 879-890
Hypoxia Imaging for Radiation Therapy Planning....Pages 891-900
Chemotherapy Combined with Radionuclide Therapy....Pages 901-908
Role of Surgery in a Multidisciplinary Approach....Pages 909-916
PET for Measuring Therapy Response After Radionuclide Therapy....Pages 917-929
Developing Probes for Molecular Imaging....Pages 931-940
Back Matter....Pages 941-951
Link Download : http://dowsA57AD1BD220CE9E0696CF1E
No comments:
Post a Comment